Ignite Creation Date:
2024-05-06 @ 9:19 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02958397
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2016-11-06
Brief Title:
A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of CD33-targeted chimeric antigen receptor TCAR-T cells in the treatment of Myeloid Malignancies
Detailed Description:
Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells However for myeloid malignancies which has higher morbidity trials of CAR-T is few CD33 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T This trial is designed and conducted to test the safety and effectiveness of CD33-targeted CAR-T
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None